Submit
  Table of Contents    
Editorial
 
Hypogonadism in men with diabetes: Should testosterone replacement therapy be based on evidence based testosterone levels and lifetime risk reduction?
Sudarshan Ramachandran1,2,3, Geoffrey I. Hackett4,5, Richard C. Strange6
1Professor of Metabolic Medicine, Department of Clinical Biochemistry, University Hospitals of North Midlands, Staffordshire, England, United Kingdom
2Professor, Faculty of Health Sciences, Staffordshire University, Staffordshire, England, United Kingdom
3Consultant Chemical Pathologist, Department of Clinical Biochemistry, Heart of England Foundation Trust, West Midlands, England, United Kingdom
4Consultant in Urology, Heart of England Foundation Trust, West Midlands, England, United Kingdom
5Professor, University of Bedfordshire, Bedfordshire, England, United Kingdom
6Professor, Metabolic Research Group, Institute of Science and Technology in Medicine, Keele University, Staffordshire, England, United Kingdom

Article ID: 100004B01SR2017
doi:10.5348/B01-2017-4-ED-4

Address correspondence to:
Professor Sudarshan Ramachandran
Department of Clinical Biochemistry, Heart of England NHS Foundation Trust
Good Hope Hospital, Rectory Road, Sutton Coldfield
West Midlands
United Kingdom

Access full text article on other devices

  Access PDF of article on other devices

[HTML FULL TEXT]   [PDF Full Text [Print This Article]
[Similar article in Pumed] [Similar article in Google Scholar]

How to cite this article
Ramachandran S, Hackett GI, Strange RC. Hypogonadism in men with diabetes: Should testosterone replacement therapy be based on evidence based testosterone levels and lifetime risk reduction? Edorium J Biochem 2017;2:1–3.


ABSTRACT

No Abstract



REFERENCES
  1. JBS3 Board. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014 Apr;100 Suppl 2:ii1–ii67.   [CrossRef]   [Pubmed]    Back to citation no. 1
  2. Ramachandran S, French JM, Vanderpump MP, Croft P, Neary RH. Should treatment recommendations for lipid lowering drugs be based on absolute coronary risk or risk reduction? BMJ 2000;320(7236):677–9.    Back to citation no. 2
  3. Hackett G, Heald AH, Sinclair A, Jones PW, Strange RC, Ramachandran S. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: Retrospective consideration of the impact of PDE5 inhibitors and statins. Int J Clin Pract 2016 Mar;70(3):244–53.   [CrossRef]   [Pubmed]    Back to citation no. 3
  4. Hackett G, Jones PW, Strange RC, Ramachandran S. Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes. World J Diabetes 2017 Mar 15;8(3):104–111.   [CrossRef]   [Pubmed]    Back to citation no. 4
  5. Dohle G, Arver S, Bettocchi C, Jones T, Kliesch S Punab M. EAU Guidelines on Male Hypogonadism. 2015. [Available at: https://uroweb.org/wp-content/uploads/18-Male-Hypogonadism_LR.pdf]    Back to citation no. 5
  6. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American college of endocrinology comprehensive cllnical practice guidelines for medical care of patients with oBesity. Endocr Pract 2016 Jul;22 Suppl 3:1–203.   [CrossRef]   [Pubmed]    Back to citation no. 6
  7. Strange RC, Burdett H, Hackett G, Ramachandran S. The metabolic syndrome: A more useful prognostic marker for CVD if testosterone and urate were included? J Endocrinol Diab Res 2016;2(1):100107.    Back to citation no. 7
  8. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012 Jun;97(6):2050–8.   [CrossRef]   [Pubmed]    Back to citation no. 8
  9. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013 Oct 21;169(6):725–33.   [CrossRef]   [Pubmed]    Back to citation no. 9
  10. Ray KK, Kastelein JJ, Boekholdt SM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: The good the bad and the uncertain: A comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014 Apr;35(15):960–8.   [CrossRef]   [Pubmed]    Back to citation no. 10

[HTML FULL TEXT]   [PDF Full Text]

Acknowledgements

The study was supported by a grant from Bayer to cover practice expenses. The sponsor had no role in the design of the study, statistical analysis, findings or preparation of manuscripts.


Author Contributions
Sudarshan Ramachandran – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Geoffrey I. Hackett – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Richard C. Strange – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guarantor of submission
The corresponding author is the guarantor of submission.
Source of support
None
Conflict of interest
Professor Geoffrey I Hackett has received honoraria for serving as a speaker for Bayer plc who provided the study grant. Professor Sudarshan Ramachandran has received honoraria for serving as a speaker for Besins Health Care Ltd. Professor Geoffrey I Hackett has spoken at various national and international meetings on testosterone and PDE5I treatments in men and sits on the committee of the European Society for Sexual Medicine.
Copyright
© 2017 Sudarshan Ramachandran et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.